- Current report filing (8-K)
06 10월 2009 - 5:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
October 5, 2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 7
Regulation FD
Item
7.01. Regulation FD Disclosure.
On
October 5, 2009,
Allos
Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing that the
Company is offering to sell, subject to market and other conditions, 11,000,000
primary shares of its common stock pursuant to an effective shelf registration
statement in an underwritten public offering.
The Company intends to grant the underwriters a 30-day option to
purchase up to an aggregate of 1,650,000 additional primary shares of common
stock to cover over-allotments, if any.
All of the shares in the offering are to be sold by the Company with
proceeds to be used to support the commercialization of FOLOTYN (pralatrexate
injection), preclinical research and clinical development of FOLOTYN, and
general corporate purposes. J.P. Morgan Securities Inc. and Citigroup Global
Markets Inc. are acting as joint book-running managers of the proposed
offering. Leerink Swann LLC is acting as
co-lead manager of the offering. JMP
Securities LLC is acting as co-manager of the Offering. A copy of the press release is filed as Exhibit 99.1
to this report and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K,
the information presented under this Item 7.01 and attached as Exhibit 99.1
shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in such filing.
Section 9
|
|
Financial
Statements and Exhibits
|
|
|
|
Item
9.01
|
|
Financial
Statements and Exhibits.
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
|
99.1
|
|
Press Release, dated
October 5, 2009, entitled Allos
Therapeutics Announces Proposed Public Offering of Common Stock.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: October 5, 2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
October 5, 2009, entitled Allos
Therapeutics Announces Proposed Public Offering of Common Stock.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024